
GOSS Stock Forecast & Price Target
GOSS Analyst Ratings
Bulls say
Gossamer Bio is on track to submit seralutinib's NDA in September for the treatment of pulmonary arterial hypertension (PAH), and potential approval is expected in the third quarter of 2027. Management has emphasized the significant unmet need in PAH and the strong data package for seralutinib, with the potential to treat a substantial portion of the PAH patient population. The company has also addressed concerns about the liver enzyme elevation and cough side effects, and is pursuing an exchange offer to address the 2027 debt maturity wall. Overall, with a credible path towards FDA approval, the current valuation of Gossamer Bio may discount a near-terminal outcome, making it a good investment opportunity in the long term.
Bears say
Gossamer Bio is facing significant risks to achieving its price target of $5 per share due to its low probability of success for its lead product seralutinib in treating PAH and PH-ILD, dilution risk from potential future capital raises, and potential disruptions to its clinical trials due to ongoing conflicts in Eastern Europe. The company's recent financial results have also fallen short of expectations, and although it has enough cash to sustain operations, its future revenues may be uncertain. Overall, these fundamental factors contribute to a negative outlook on Gossamer Bio's stock.
This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GOSS Analyst Forecast & Price Prediction
Start investing in GOSS
Order type
Buy in
Order amount
Est. shares
0 shares